KAPIL COTEX LIMITED

1. Introduction:

• Brief introduction of the company: 

A twist in direction came late 2024 - Kapil Cotex Ltd., once rooted in textiles since its start back in 1983, began reshaping itself. By early 2025, fresh paths emerged under a new name: Skybiotech Healthcare Ltd. Textile threads gave way to science-driven work, shifting fully into medicine and health-related fields. Change didn’t arrive slowly; it took hold fast, redefining what the firm stands for.

• Industry overview: 

The shift begins now - away from flat performance in textiles toward momentum in India’s pharma and biotech space. Growth here ties closely to stronger health needs, along with increasing overseas sales potential. Movement across sectors reflects a deeper realignment, not just a change in name or paperwork. What was slow now meets what expands.

• Purpose of the analysis:

To see how the firm shifted - once empty, now alive - with money flowing into medicine work after sitting still in the textile.

2. Company Overview:

• Background and history: 

A quiet rhythm marked Kapil Cotex’s path - years unfolded without much core trade. Earnings came not from bustling operations, but through advisory roles instead. Investment returns fed the flow long before anything else took shape.

• Business model: 

A different way to run things has started. Making medicine is now part of what they do. Selling those medicines follows close behind. Ownership began when they took control of Skybiotech Life Sciences. That company is a private organisation. They bought just over 72%. The move happened during fiscal year 2025.

• Key products/services: 

As of 2025, healthcare items stand alongside medicines you take daily. Formulations appear everywhere from hospitals to homes. Active components shape what these treatments do inside bodies.

• Market position: 

Kapil Cotex Ltd. is a tiny player trying to rebuild, it's just stepping into healthcare with fresh production plans taking shape. Even though it is in early days, the push to grow has already started.

3. Promoter/ Founder Introduction:  

• Name of promoter(s)/founder(s): 

Behind the company stands Prakashchandra Rathi, serving as Chairman and CFO. Leadership also flows through Poonam Rathi, who runs operations as Managing Director. One shapes finance and vision, while the other drives daily direction forward.

• Professional background: 

Ownership begins with the Rathi family, controlling 63.48% of the firm. Three decades back, Prakashchandra Rathi stepped into finance and has stayed deep in business operations ever since.

• Role in company growth and strategic decisions: 

Shifting focus came from leadership choices made during tough market shifts. Buying Skybiotech wasn’t just about equipment - it brought skilled people too. A new direction started before competitors noticed. Expertise flowed in once deals closed. Decisions like that changed what kind of business they became. Growth followed after new systems took root.

4. Financial Statement Analysis:
5. 1. Income Statement Analysis:

Trends: The sharp revenue jump in FY 25 represents the first year of pharmaceutical operations. The    loss is attributed to one-time acquisition costs and initial operational scaling.

2. Balance Sheet Analysis: 

• Assets: Total assets surged to ₹12.30 Cr in FY 25, compared to ~₹4.06 Cr in FY 23, primarily due to the addition of fixed assets (land, plant, and machinery) from the biotech acquisition.
• Liabilities: Total liabilities stand at ₹9.56 Crores.
• Equity: Total Equity (Net Worth) has grown to ₹10.54 Cr following capital infusion and asset revaluation.

3. Cash Flow Statement Analysis: 

4. Key Financial Ratios:

• Liquidity: Current Ratio is 0.75, indicating a need for better working capital management.
• Efficiency: Inventory turnover and debtor days are currently stabilizing as operations are fresh.
• Profitability: Operating Margin is negative (-32%) due to the high gestation cost of the new business.

5. Key Insights and Interpretation:

• Strengths: 

What stands out is how smoothly they moved into a busy market area. Their pile of assets got much bigger over time. Not owing money gives them room to move. Years spent in textile work show up clearly in their approach.

• Weaknesses: 

Money going out is more than coming in right now. Operations drained funds instead of adding them last year. The small size holds it back. Outdated systems slow down the progress.

• Risk factors: 

Competition in the sector runs deep. When it comes to rules, medicine faces tighter controls compared to fabric production. Stuck routines push companies out of touch with demand.

• Future outlook: 

A turnaround might depend on branching out or joining forces. Survival looks shaky without a solid reset plan kicking in. Hitting target output levels in medicines may balance the books by 2027.

6. Conclusion:

• Final evaluation of financial health: 

Now looking at the full picture - Skybiotech Healthcare, once known as Kapil Cotex, carries strong upside but also serious risk. Its finances are still shaky amid ongoing changes, marked by tight cash flow and continued net losses. Yet here's something different: after many years, it has finally built a working engine that brings in steady income.

• Investment or performance perspective: 

Expect big swings but small gains. Only those chasing guesses should step in. For Long-term funds, better look elsewhere.

• References:
• https://www.kapilcotexlimited.com/_files/ugd/64edce_533b711578984ddbb254c4b1b7b2fb3a.pdf
• Annual reports of 3 financial years.